Trial Profile
Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms CAMARA
- 05 Apr 2022 Primary endpoint (Evaluation of the quality of life of patients with iron deficiency with or without anemia during treatment for their cancer) has been met, according to Results published in the Oncologist.
- 05 Apr 2022 Results published in the Oncologist
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress